149845-07-8
![149845-07-8 结构式](/CAS/GIF/149845-07-8.gif)
基本信息
(4-氯苯硫基)甲叉二膦酸二钠
SR-41319B
SR 41319G
Unii-bh6m93cia0
DisodiuM Tiludronate
TILUDRONIC ACID, DISODIUM SALT
Disodium (4-chlorophenylthio)methylenediphosphonate
[[(4-CHLOROPHENYL)THIO]METHYLENE]BIPHOSPHONIC ACID, DISODIUM SALT
[[(4-Chlorophenyl)thio]methylene]biphosphonicAcid,DisodiumSalt,SR-41319B,Skelid
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2024/04/30 | D4167 | 替鲁膦酸二钠 Disodium Tiludronate | 149845-07-8 | 25mg | 1405元 |
常见问题列表
The ability of Tiludronate to inhibit proton transport is 5-fold higher in kidney-derived vesicles (IC 50 =1.1 mM) and 10,000-fold higher in vesicles derived from osteoclasts (IC 50 =466 nM). Tiludronate also potently inhibits proton transport in yeast microsomal preparations (IC 50 =3.5 microM) and inhibits the activity of purified yeast V-ATPase. The inhibition of the osteoclast V-ATPase-mediated proton transport by Tiludronate is rapid, pH-dependent, and reversible.
Tiludronate exerts a dose-dependent inhibitory activity on bone resorption. Tiludronate could act on mature osteoclasts by reducing their capacity to secrete proton into the resorption space and also by favoring their detachment from the bone matrix. Tiludronate is also tested in other models of osteoporosis. In the castrated male rat model, Tiludronate (5-200 mg/kg; p.o.) prevents the decrease in the skeletal mass, assessed physically by measuring the bone weight and density or chemically by determining the calcium and phosphate content.